{
    "nct_id": "NCT03354143",
    "title": "Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)",
    "status": "COMPLETED",
    "last_update_time": "2025-06-30",
    "description_brief": "The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults. Amyloid beta protein is high in the brain of older adults with Alzheimer's disease. Hypertension may increase brain amyloid beta protein accumulation and affect memory and thinking ability in older adults. However, whether lowering blood pressure reduces brain amyloid beta protein and improves brain function is inconclusive.\n\nThe investigators hypothesize that treating high blood pressure alters brain pulsatility, which in turn reduces brain amyloid beta protein accumulation and improves brain structure and function.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": {
        "participantFlowModule": {
            "preAssignmentDetails": "85 participants enrolled include 40 (Control group subjects-no intervention) and 45 participants (undergo intervention). These 45 subjects are randomized to either Standard care or Intensive care interventions that is summarized in the table below. Control group was not randomized and they did not receive an experimental intervention but received SOC.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Standard Care",
                    "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                },
                {
                    "id": "FG001",
                    "title": "Intensive Treatment",
                    "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                },
                {
                    "id": "FG002",
                    "title": "Control Group",
                    "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "40"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "17"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "22"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "40"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "4"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "0"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "populationDescription": "85 participants enrolled include 40 (Control group subjects-no intervention) and 45 participants (undergo intervention). These 45 subjects are randomized to either Standard care or Intensive care interventions that is summarized in the table below. The baseline characteristics of the 40 subjects in Control group (no intervention) were not collected.",
            "groups": [
                {
                    "id": "BG000",
                    "title": "Standard Care",
                    "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                },
                {
                    "id": "BG001",
                    "title": "Intensive Treatment",
                    "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                },
                {
                    "id": "BG002",
                    "title": "Control Group",
                    "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "19"
                        },
                        {
                            "groupId": "BG001",
                            "value": "26"
                        },
                        {
                            "groupId": "BG002",
                            "value": "40"
                        },
                        {
                            "groupId": "BG003",
                            "value": "85"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Categorical",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "<=18 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Between 18 and 65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "5"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "42"
                                        }
                                    ]
                                },
                                {
                                    "title": ">=65 years",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "43"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "68.9",
                                            "spread": "5.8"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "62.8",
                                            "spread": "6.4"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "60.3",
                                            "spread": "6.6"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "65.5",
                                            "spread": "6.7"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "9"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "22"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "47"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "18"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "38"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "6"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "6"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "11"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "12"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "35"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "68"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Region of Enrollment",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "participants",
                    "classes": [
                        {
                            "title": "United States",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "19"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "26"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "40"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "45"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Changes in Gray Matter Intracranial Pulsatility",
                    "description": "Changes (12 month timepoint minus baseline) in intracranial pulsatility will be measured with CINE phase-contrast MRI. We will use the velocity-encoded CINE PC MRI to measure intracranial pulsatility. Pulsatility measured in mm per cardiac cycle",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mm/cardiac cycle",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.09",
                                            "spread": "0.04"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.02",
                                            "spread": "0.03"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Changes in Overall Average 24 Hour Systolic Blood Pressure",
                    "description": "changes in overall average 24 hr ambulatory systolic blood pressure will be assessed SpaceLabs monitor",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mmHg",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17.9",
                                            "spread": "3.3"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "23.6",
                                            "spread": "2.8"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Changes in Overall Average 24hr Diastolic Blood Pressure",
                    "description": "changes in overall average 24 hr ambulatory diastolic blood pressure will be assessed SpaceLabs monitor",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mmHg",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "19"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "26"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "10.9",
                                            "spread": "1.5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "12",
                                            "spread": "1.2"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Regional Cortical Thickness Via Magnetic Resonance Imaging (MRI)",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "mm",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "15"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.3",
                                            "spread": "0.09"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.4",
                                            "spread": "0.08"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.3",
                                            "spread": "0.09"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.3",
                                            "spread": "0.09"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Brain White Matter Hyperintensity (WMH) Via Magnetic Resonance Imaging (MRI)",
                    "description": "White matter hyperintensities (WMH) on brain T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance images (MRI) are commonly observed in older adults over 65 years old, and more extensive in those with vascular or Alzheimer's disease type of dementia. Qualitative and quantitative WMH characterization has been used as a biomarker to assist cerebral small vessel disease diagnosis and to assess treatment effects. In this report, the size of the WMH has been assessed with the PGS software, the top performer of the deep-learning algorithms from the 2017 MICCAI WMH segmentation challenge. The unit of the WMH total size presented in this report is in mL.",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "ml",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "15"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.9",
                                            "spread": "12.9"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.8",
                                            "spread": "3.2"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 Month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "7.5",
                                            "spread": "13.0"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "2.6",
                                            "spread": "2.9"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Brain White Matter Microstructural Integrity Via Magnetic Resonance Imaging (MRI)",
                    "description": "Fractional Anisotropy (FA) values are a measure of how directed diffusion is in a tissue, typically ranging from 0 to 1. A value of 0 indicates isotropic diffusion (diffusion is the same in all directions), while a value of 1 indicates highly anisotropic diffusion (diffusion is restricted to a single direction). FA is often used in diffusion tensor imaging (DTI) and is thought to reflect fiber density, axonal diameter, and myelination in white matter.",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Mean fractional anisotropy from DTI",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "15"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.4",
                                            "spread": "0.02"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.4",
                                            "spread": "0.02"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 Month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.4",
                                            "spread": "0.01"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.4",
                                            "spread": "0.01"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Brain Neural Network Functional Connectivity Via Magnetic Resonance Imaging (MRI)",
                    "description": "The brain's functional connectivity, particularly within the Default Mode Network (DMN), can be assessed using functional magnetic resonance imaging (fMRI) through the correlations between the activity of the brain regions within a network. In this report, the DMN regions were identified with a seed-based approach from another clinical trial with 420 subjects of a similar population. By identifying regions of interest (ROIs) within the DMN, researchers can analyze how these regions connect and interact with each other, revealing information about brain activity and potentially aiding in the diagnosis and understanding of various neurological and psychiatric conditions. Here, the functional connectivity of the DMN brain regions is reported in the unit of Pearson correlation R, with a range of 0 to 1 in this application. A high R value indicates a high level of connectivity.",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "Pearson correlation R (r value)",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "14"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "21"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.39",
                                            "spread": "0.083"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.42",
                                            "spread": "0.14"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 Month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.39",
                                            "spread": "0.079"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.4",
                                            "spread": "0.08"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "NIH PROMIS Patient-reported Outcome Measures of Physical Health",
                    "description": "PROMIS\u00ae (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric:\n\nA score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function).A score of 60 is one standard deviation above the average population",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "T score",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "17"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "52.1",
                                            "spread": "6.4"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "51.0",
                                            "spread": "6.3"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 Month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "50.9",
                                            "spread": "7.5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "51.8",
                                            "spread": "7.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "NIH PROMIS Patient-reported Outcome Measures of Mental Health",
                    "description": "PROMIS\u00ae (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). A score of 60 is one standard deviation above the average population",
                    "populationDescription": "Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol.",
                    "reportingStatus": "POSTED",
                    "paramType": "MEAN",
                    "dispersionType": "Standard Deviation",
                    "unitOfMeasure": "T sore",
                    "timeFrame": "Baseline and 12-months",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Standard Care",
                            "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg."
                        },
                        {
                            "id": "OG001",
                            "title": "Intensive Treatment",
                            "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg."
                        },
                        {
                            "id": "OG002",
                            "title": "Control Group",
                            "description": "Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP\\<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC)."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "17"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "24"
                                },
                                {
                                    "groupId": "OG002",
                                    "value": "0"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Baseline",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "56.0",
                                            "spread": "7.5"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "52.1",
                                            "spread": "7.4"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "12 Month",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "54.9",
                                            "spread": "8.4"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "54.0",
                                            "spread": "6.3"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "0",
            "timeFrame": "12 months",
            "description": "Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Standard Care",
                    "description": "Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 130 mmHg. Drug doses will be titrated to reach the BP target.\n\nStandard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 130 mmHg.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 19,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 19,
                    "otherNumAffected": 8,
                    "otherNumAtRisk": 19
                },
                {
                    "id": "EG001",
                    "title": "Intensive Treatment",
                    "description": "Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP \u2264 120 mmHg.\n\nIntensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP \u2264 120 mmHg.",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 26,
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 26,
                    "otherNumAffected": 7,
                    "otherNumAtRisk": 26
                }
            ],
            "otherEvents": [
                {
                    "term": "Abnormal laboratory measure",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "notes": "low serum sodium",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 0,
                            "numAffected": 0,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 26
                        }
                    ]
                },
                {
                    "term": "Orthostatic hypotension",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 2,
                            "numAffected": 2,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 26
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "General disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 4,
                            "numAffected": 4,
                            "numAtRisk": 26
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "assessmentType": "NON_SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numEvents": 5,
                            "numAffected": 5,
                            "numAtRisk": 19
                        },
                        {
                            "groupId": "EG001",
                            "numEvents": 1,
                            "numAffected": 1,
                            "numAtRisk": 26
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": true,
                "restrictiveAgreement": false
            },
            "pointOfContact": {
                "title": "Dr. Rong Zhang",
                "organization": "IEEM",
                "email": "rongzhang@texashealth.org",
                "phone": "214-345-4245"
            }
        }
    },
    "target_category": "N/A",
    "drug": [
        "Amlodipine (calcium\u2011channel blocker)",
        "Losartan (angiotensin II receptor blocker)",
        "Other FDA\u2011approved antihypertensive medications (standard care / intensive treatment arms)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests whether lowering blood pressure with FDA\u2011approved antihypertensive medications alters intracranial pulsatility and thereby reduces brain amyloid\u2011\u03b2 accumulation and improves brain structure/function. The intervention is routine antihypertensive therapy, not a drug specifically designed to bind or remove amyloid or tau (i.e., not an Alzheimer\u2019s\u2011pathology\u2011targeted biologic or small molecule). \ue200cite\ue202turn0search1\ue202turn1search0\ue201",
        "Act: Trial registry entries list two randomized arms (standard care vs intensive treatment). The intensive arm includes amlodipine (a calcium\u2011channel blocker) and losartan (an angiotensin II receptor blocker) with titration of doses to achieve a 24\u2011hour SBP \u2264120 mmHg; other common antihypertensives may be used per protocol. These are cardiovascular small molecules used to lower blood pressure rather than agents developed to directly target amyloid pathology. \ue200cite\ue202turn0search1\ue202turn0search3\ue201",
        "Reflect: Given the category definitions, this trial does not fit cleanly into: (1) disease\u2011targeted biologic (no biologic/antibody/vaccine targeting amyloid or tau), (2) disease\u2011targeted small molecule (the drugs do not directly target Alzheimer\u2019s pathology though the study hypothesizes an indirect effect), (3) cognitive enhancer (the drugs are not primarily cognitive\u2011enhancing agents), or (4) neuropsychiatric symptom improvement. Therefore the correct classification is 'N/A'. Key sources: trial registry entries showing HIPAC (NCT03354143) and the listed antihypertensive agents. \ue200cite\ue202turn1search0\ue202turn0search1\ue201"
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}